Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  azacitidine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 79 for your search:
Start Over
Randomized Allogeneic Azacitidine Study
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2008-0503, NCI-2012-01259, NCT00887068
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Phase: Phase III
Type: Treatment
Status: Active
Age: 55 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-486-AML-001, 2012-003457-28, NCT01757535
Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0737, NCI-2013-00704, NCT01787487
A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 112121, NCT02158936
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: FLUGAZA, NCT02319135
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase: Phase III
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2215-CL-0301, 2015-000140-42, NCT02421939
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: HCI53993, NCT00748553
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0907010513, NCT01004991
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI
Protocol IDs: CASE1908, NCI-2009-01285, NCT01093573
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0912010795, NCT01120834
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE1A09, NCI-2010-01139, NCT01155583
Treatment of Acute Leukemia Relapse After Allotransplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 90
Sponsor: Other
Protocol IDs: Allo-Relapse-2011, NCT01369368
Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2011-0188, NCI-2012-01350, NCT01636609
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 201303012, NCT01747499
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-486-AML-002, NCT01835587
AC220 With 5-Aza or Low Dose Cytarabine
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-1047, NCI-2013-02274, P50 CA100632, NCT01892371
Oral Rigosertib in Combination With Azacitidine
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Onconova 09-08, 2013-000673-72, NCT01926587
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: 2013-0186, NCI-2014-01025, NCT01983969
Romidepsin + Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AAAM3752, NCT01998035
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0103-014, NCT02018926
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0706, NCI-2014-01114, NCT02096042
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: OTX015_206, NCT02303782
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARO-010, NCT02400281
Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: TASMC-08-MM-TLV-0069-08-CTIL, NCT00704704
Start Over